Novel Cancer Antibody Targets Unique Epitope Across Species
Novel Cancer Antibody Targets Unique Epitope Across Species
Treg-depleting Anti-CCR8 Antibody for Treatment of Cancer
Tags: Monash University, Australia, Healthcare & Lifesciences
The Monash anti-CCR8 monoclonal antibody targets tumor-infiltrating Tregs to enhance anti-tumor responses, showing promise in various solid tumors. This antibody depletes Tregs in the tumor microenvironment, aiming to improve outcomes in cancers like lung and breast cancer. It has reached the lead candidate stage with completed humanization, standing out for targeting a unique epitope across species, facilitating faster pre-clinical development. Demonstrating synergy with anti-PD-1 antibodies in mouse models, it holds a strong IP position. This innovation presents a significant step forward in immuno-oncology, offering a new therapeutic approach to cancer treatment.
IP Type or Form Factor: Patent Pending; Platform
TRL: 5 - prototype ready for testing in intended environment
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
